







Any combination of Pfizer or AstraZeneca for first and second doses works, a study suggests.
Vaccination Dramatically Lowers Long COVID Risk
Several new studies reveal that getting multiple COVID vaccine doses provides strong protection against lingering symptoms

The 300-year journey to the covid vaccine: From inoculation to RNA
The history of immunization technology is a quest to achieve immunity with ever-more safety and ever-fewer side effects
My doctor sent over some information about treatment. If you get COVID and you are high risk talk to your doctor ASAP for prescription meds. Here’s a list of OTC meds One Medical recommends for fighting off COVID symptoms if you aren’t high risk and when to seek further help.
My doctor sent over some information about treatment.If you get COVID and you are high risk talk to your doctor ASAP for prescription meds.Here’s a list of OTC meds One Medical recommends for fighting off COVID symptoms if you aren’t high risk and when to seek further help. pic.twitter.com/e8fGR5Llte— Sasha Perigo (@sashaperigo) May 19, 2022
COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season
Importance SARS-CoV-2 remains a substantial cause of respiratory illness, morbidity, and mortality. Evidence to date has demonstrated that COVID-19 vaccines reduce the risk of severe disease, including hospitalization and death. Objective This systematic review identifies and summarizes newly published studies reporting on the effectiveness and safety of COVID-19 vaccines and COVID-19 epidemiology in the US. Evidence Review Cochrane Central Register of Controlled Trials, PubMed/MEDLINE, Embase, and Scopus were searched from August 1, 2025, through June 29, 2026. Studies were eligible if they reported on the effectiveness, efficacy, or safety of a US-licensed COVID-19 vaccine or SARS-CoV-2 epidemiology in the US. Findings From 11 829 identified references, 155 publications were eligible (15 randomized clinical trials, 84 observational studies with a comparator group, 38 product safety studies without a comparator group [single group], and 18 descriptive studies of disease burden). Consistent with prior evidence, studies reported that updated COVID-19 vaccines were associated with a reduction in the risk of hospitalization among both older adults (≥65 years; vaccine effectiveness [VE], 53.0%; 95% CI, 37.0%-65.0%; 2025-2026 season) and adults (18-64 years; VE, 54.0%; 95% CI, 1.0%-78.0%; 2024-2025 season). Maternal vaccination was associated with reduced risk of COVID-19–associated emergency department/urgent care encounters among individuals vaccinated (VE, 58.0%; 95% CI, 24.0%-77.0%) and with fewer COVID-19–related hospital contacts in the first 2 months of life among infants born subsequently (VE range, 50.0%-54.0%), regardless of trimester of vaccination. Vaccination was also associated with a significant reduction in COVID-19–related pediatric emergency department visits (9 months to 4 years; VE, 76.0%; 95% CI, 58.0%-87.0%). Vaccination was associated with a reduced risk of critical COVID-19 illness (intensive care unit admission or death) in immunocompromised adults (VE range, 32.0%-53.0%, depending on condition and other factors). Health care personnel who received 3 to 5 vaccine doses were less likely to develop laboratory-confirmed COVID-19 illness (VE, 41.0%; 95% CI, 34.0%-47.0%) and postacute COVID-19 symptoms (VE, 57.0%; 95% CI, 46.0%-66.0%) compared with those who received only 2 doses. Across adverse events of special interest (eg, stroke, thrombosis, myocarditis), safety profiles were consistent with those of previous reviews. No identified studies conducted under the updated guidance on extended dosing intervals for the primary series reported an increased risk of myocarditis or pericarditis. No new safety signals were reported in the recently published studies eligible for this updated review of US-licensed COVID-19 vaccines. Conclusions and Relevance COVID-19 vaccines were consistently associated with a reduction in the risk of hospitalization and other outcomes, including among individuals at high risk of severe COVID-19, such as infants, and those who were pregnant. No new safety concerns were identified.

The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
Objective:We performed a systematic literature review and meta-analysis on the effectiveness of coronavirus disease 2019 (COVID-19) vaccination against post-COVID conditions (long COVID) among fully vaccinated individuals.Design:Systematic literature review/meta-analysis.Methods:We searched PubMed, Cumulative Index to Nursing and Allied Health, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science from December 1, 2019, to June 2, 2023, for studies evaluating the COVID-19 vaccine effectiveness (VE) against post-COVID conditions among fully vaccinated individuals who received two doses of COVID-19 vaccine. A post-COVID condition was defined as any symptom that was present four or more weeks after COVID-19 infection. We calculated the pooled diagnostic odds ratio (DOR) (95% confidence interval) for post-COVID conditions between fully vaccinated and unvaccinated individuals. Vaccine effectiveness was estimated as 100% x (1-DOR).Results:Thirty-two studies with 775,931 individuals evaluated the effect of vaccination on post-COVID conditions, of which, twenty-four studies were included in the meta-analysis. The pooled DOR for post-COVID conditions among fully vaccinated individuals was 0.680 (95% CI: 0.523–0.885) with an estimated VE of 32.0% (11.5%–47.7%). Vaccine effectiveness was 36.9% (23.1%–48.2%) among those who received two doses of COVID-19 vaccine before COVID-19 infection and 68.7% (64.7%–72.2%) among those who received three doses before COVID-19 infection. The stratified analysis demonstrated no protection against post-COVID conditions among those who received COVID-19 vaccination after COVID-19 infection.Conclusions:Receiving a complete COVID-19 vaccination prior to contracting the virus resulted in a significant reduction in post-COVID conditions throughout the study period, including during the Omicron era. Vaccine effectiveness demonstrated an increase when supplementary doses were administered.

Repurposing the estrogen receptor modulator raloxifene to treat SARS-CoV-2 infection
The ongoing coronavirus disease 2019 (COVID-19) pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) necessitates strategies to identify prophylactic and therapeutic drug candidates to enter rapid clinical development. This is particularly true, given the uncertainty about the endurance of the immune memory induced by both previous infections or vaccines, and given the fact that the eradication of SARS-CoV-2 might be challenging to reach, given the attack rate of the virus, which would require unusually high protection by a vaccine. Here, we show how raloxifene, a selective estrogen receptor modulator with anti-inflammatory and antiviral properties, emerges as an attractive candidate entering clinical trials to test its efficacy in early-stage treatment COVID-19 patients.

I've discovered a probiotic that seems to reduce the infection rate and severity of SARS-CoV-2, as well as other diseases. I'm going to link multiple studies in this thread. Parents of young children especially, you'll want to pay attention t
I've discovered a probiotic that seems to reduce the infection rate and severity of SARS-CoV-2, as well as other diseases. I'm going to link multiple studies in this thread. Parents of young children especially, you'll want to pay attention to this:— 𓅔 Don't cede ground to disease 𓄿 𓅀 𓅁 𓅂 𓅃 𓅄 (@TheManeCharactr) December 20, 2023
Experimental peptides are being advertised for Long COVID. But the evidence is trailing behind. - The Sick Times
Some FDA-approved GLP-1s are being studied in clinical trials for the disease, but their results aren’t available yet. Experts caution against using experimental peptides for Long COVID.

Long-COVID recovery varies sharply by symptoms, study finds
Fewer than one in five people with multiple body systems impacted experience sustained improvement within three years of infection, a study found.

People With Multisystem Long Covid See Lower Recovery, Research Finds
People whose long Covid affects multiple body systems are far less likely to improve than overall recovery estimates suggest, with fewer than one in five experiencing sustained improvement within three years of infection, according to a US study.

F.D.A. Approves New Covid Vaccines, and They Should Be Available Soon
The shots have been approved for people 65 and older, and for younger people with underlying conditions. Others may be able to get them off label.

Elusive immune cells dwelling in 'hidden niches' of the bone marrow may be key to SARS-CoV-2 vaccination
Although immunologists have developed a deep reservoir of knowledge illuminating how antibodies respond to vaccination against SARS-CoV-2, little is known about the elusive cells that produce infection-fighting ...

Comparing the COVID-19 Vaccines: How Are They Different?
Keeping up with COVID-19 vaccines can be a daunting task. To help people keep up, Yale Medicine mapped out a comparison of the most prominent ones.
Scientists Like Me Knew There Was Something Amiss With Andrew Huberman’s Wildly Popular Podcast
He recommends supplements. He’s iffy on the flu shot. And more.

Yale School of Public Health - COVID-19 and Immune System Impacts
THIS IS HUGE! Researchers at Stanford University have developed a dual-antibody treatment that remains effective against ALL SARS-CoV-2 variants by targeting a less-mutable part of the virus. This breakthrough could lead to longer-lasting therapies that OUTPACE viral evolution. 🧪🧵⬇️